Related Experiment Video

Updated: Jun 14, 2025

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

18.0K

TIGIT: Will it be the next star therapeutic target like PD-1 in hematological malignancies?

Yang Liu1, Wenhui Liu1, Tao Wu1

  • 1The 940th Hostipal of Joint Logistics Support force of Chinese People's Liberation Army, China.

Critical Reviews in Oncology/Hematology
|September 5, 2024
PubMed

Insights

T cell immunoreceptor with immunoglobulin and ITIM domains (TIGIT) shows promise as a novel therapeutic target for hematologic malignancies. Further research into TIGIT

Area of Science:

  • Immunology
  • Oncology
  • Hematology

Background:

  • Checkpoint inhibitory receptors, like PD-1 and CTLA-4, are crucial in hematologic disease research.
  • Relapsed/refractory hematologic malignancies and resistance to PD-1/CTLA-4 therapies necessitate new targets.
  • The T cell immunoreceptor with immunoglobulin and ITIM domains (TIGIT) pathway's role in these diseases requires further investigation.

Purpose of the Study:

  • To review the mechanism of the TIGIT pathway.
  • To explore TIGIT's combined effects with other immune checkpoints.
  • To discuss TIGIT's potential as a therapeutic target in hematologic malignancies.

Main Methods:

  • Literature review of TIGIT mechanism and applications.
  • Analysis of TIGIT's role in immune-related therapy.
  • Examination of TIGIT's impact on hematopoietic stem cell transplantation (HSCT) and the tumor microenvironment (TME).

Main Results:

  • TIGIT functions as an inhibitory receptor with potential similar to PD-1.
  • Combined immunotherapies involving TIGIT may offer synergistic effects.
  • TIGIT influences the tumor microenvironment and HSCT outcomes.

Conclusions:

  • TIGIT presents a promising therapeutic target for hematologic malignancies.
  • Understanding TIGIT's specific mechanisms is vital for clinical application.
  • TIGIT-based strategies could overcome resistance to current immunotherapies.
Keywords:
Checkpoint inhibitory receptorsImmunotherapyLeukemiaT cell immunoreceptor with immunoglobulin and ITIM domains

More Related Videos

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.1K
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.4K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
493
Role of Hematopoietic Growth Factors01:28

Role of Hematopoietic Growth Factors

Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
1.3K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.4K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.0K